Asset
GALSULFASE
BioMarin Pharmaceutical Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00299000 | phase4 | completed | 2006-05-01 | 2009-04-01 | BioMarin Pharmaceutical | A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 125117 | BLA | BioMarin Pharmaceutical Inc. |
Marketed products (1)
- NAGLAZYME